HENGAN INT'L (01044) appoints Pang Yaoci as Company Secretary.

16:52 31/03/2026

Heng An International (01044) announced that Mr. Li Weiliang has resigned as an executive director of the company, group chief financial officer, and company secretary to pursue other career opportunities, effective from April 1, 2026. From the same date, Mr. Li will also cease to act as the authorized representative of the company under Rule 3.05 of the Listing Rules of the Stock Exchange, as well as the authorized representative of the company to accept any legal process documents or notices under Part 16 of the Companies Ordinance (Chapter 622 of Hong Kong Law).

HENGAN INT'L (01044) announces that Mr. Li Weiliang has resigned from his positions as Executive Director, Group Chief Financial Officer, and Company Secretary of the company to pursue other career opportunities, effective from April 1, 2026. On the same day, Mr. Li will also cease to act as the Company's authorized representative under Rule 3.05 of the Listing Rules of the Stock Exchange of Hong Kong, and as the authorized representative of the Company to accept any legal process or notices under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong). The Board is pleased to announce that Mr. Pang Yaoci has been appointed as the Company Secretary, authorized representative under the Listing Rules, and authorized representative under Part 16 of the Companies Ordinance, effective from April 1, 2026.

MICROTECH MED-B(02235) invested 641,000 Hong Kong dollars on March 31 to repurchase 88,000 shares.

Shanghai Fosun Pharmaceutical (02196): FXB0871 approved for clinical trials in locally advanced or metastatic solid tumors.

CHINA PENGFEI (03348) released its annual performance with a net profit attributable to shareholders of 101 million yuan, an increase of 50.02% year-on-year.

MICROTECH MED-B(02235) invested 641,000 Hong Kong dollars on March 31 to repurchase 88,000 shares.

Shanghai Fosun Pharmaceutical (02196): FXB0871 approved for clinical trials in locally advanced or metastatic solid tumors.

CHINA PENGFEI (03348) released its annual performance with a net profit attributable to shareholders of 101 million yuan, an increase of 50.02% year-on-year.